Form 4: Lyell Immunopharma Director Acquires 260,000 Options
SEC Form 4 Filing
Director Sumant Ramachandra acquired 260,000 options of Lyell Immunopharma, Inc. at a price of $0.9603 on October 31, 2024.
Summary
- On October 31, 2024, Sumant Ramachandra, a director of Lyell Immunopharma, Inc., acquired 260,000 options to purchase common stock.
- The exercise price of these options is $0.9603.
- The options vest monthly over a three-year period, starting from the grant date, subject to continued service.
- The expiration date for these options is October 30, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing reflects insider activity, which is common in publicly traded companies. Monitoring such filings can provide insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The acquisition of options by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/31/2024 | Date of transaction: Director Sumant Ramachandra acquired 260,000 options. |
| 10/30/2034 | Expiration date of the options. |
| 11/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.